[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Sarepta Sarepta Therapeutics Sarepta Therapeutics posts on X about arrowhead the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::2216555822/interactions)  - X Week XXXXXX +2,401% - X Month XXXXXX +38% - X Months XXXXXX +6,846% - X Year XXXXXX -XX% ### Mentions: XX [#](/creator/twitter::2216555822/posts_active)  ### Followers: XXXXX [#](/creator/twitter::2216555822/followers)  - X Week XXXXX +2.20% - X Month XXXXX +3.40% - X Months XXXXX +7% - X Year XXXXX +12% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::2216555822/influencer_rank)  ### Social Influence [#](/creator/twitter::2216555822/influence) --- **Social topic influence** [arrowhead](/topic/arrowhead) XXXX% **Top accounts mentioned or mentioned by** [@yachmod](/creator/undefined) [@parentprojectmd](/creator/undefined) [@cphilstrom](/creator/undefined) [@genbio](/creator/undefined) [@mdaorg](/creator/undefined) [@alexwestchester](/creator/undefined) [@jmaraganore](/creator/undefined) [@yasiejko](/creator/undefined) [@marksharkking](/creator/undefined) [@braincures](/creator/undefined) [@prismdm](/creator/undefined) [@mmgtrinity](/creator/undefined) [@jr2251](/creator/undefined) [@duncanburnsma](/creator/undefined) [@zinselmeyerb](/creator/undefined) [@pharmacompass](/creator/undefined) [@rwarner42](/creator/undefined) [@superduperdrugs](/creator/undefined) [@yaireinhorn](/creator/undefined) [@checkorphan](/creator/undefined) ### Top Social Posts [#](/creator/twitter::2216555822/posts) --- Top posts by engagements in the last XX hours "News: The U.S. FDA granted Platform Technology Designation to SRP-9003 Sareptas investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1930272306384793816) 2025-06-04 14:35:55 UTC 6159 followers, 7949 engagements "Today we announced that enrollment & dosing is complete in Study SRP-9003-301 a Phase X multi-national open-label study of investigational candidate SRP-9003 for the treatment of LGMD2E/R4. Data are expected in the first half of 2025"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1869376529836503101) 2024-12-18 13:37:50 UTC 6156 followers, 3310 engagements "Today we shared updates from our clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5 2D/R3 and 2E/R4. Read more here:"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1912122376738779536) 2025-04-15 12:34:34 UTC 6153 followers, 3401 engagements "On this #RareDiseaseDay were excited to announce the launch of Route XX The Duchenne Scholarship Program. Were awarding up to XX scholarships to individuals living with Duchenne and up to X scholarships to siblings. Learn more:"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1895475979042369781) 2025-02-28 14:07:44 UTC 6156 followers, 1169 engagements "Excited to be a partner of the 2025 @MDAorg Clinical & Scientific Conference. Well be there celebrating XX years of #MDA impact & sharing updates on how Sarepta is advancing science for Duchenne and LGMD patients. #MDAconference"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1900643260193784031) 2025-03-14 20:20:40 UTC 6154 followers, 2760 engagements "Attending #ASGCT2025 Explore our posters and oral presentations. Learn more here:"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1923409078182683050) 2025-05-16 16:03:54 UTC 6154 followers, 1550 engagements "CEO Doug Ingram on Sareptas global licensing and collaboration agreement with Arrowhead Pharmaceuticals and how the agreement will help solidify Sareptas position as a genetic medicine leader"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1861418651364082108) 2024-11-26 14:36:04 UTC 6144 followers, 1802 engagements "Today we released our financial results for Q4 and the full year of 2024 showing a XX% increase in net product revenue over the same quarter of the prior year. Our president and CEO on the results:"  [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1894884362237186122) 2025-02-26 22:56:51 UTC 6142 followers, 1543 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sarepta Therapeutics posts on X about arrowhead the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social topic influence arrowhead XXXX%
Top accounts mentioned or mentioned by @yachmod @parentprojectmd @cphilstrom @genbio @mdaorg @alexwestchester @jmaraganore @yasiejko @marksharkking @braincures @prismdm @mmgtrinity @jr2251 @duncanburnsma @zinselmeyerb @pharmacompass @rwarner42 @superduperdrugs @yaireinhorn @checkorphan
Top posts by engagements in the last XX hours
"News: The U.S. FDA granted Platform Technology Designation to SRP-9003 Sareptas investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at" @Sarepta on X 2025-06-04 14:35:55 UTC 6159 followers, 7949 engagements
"Today we announced that enrollment & dosing is complete in Study SRP-9003-301 a Phase X multi-national open-label study of investigational candidate SRP-9003 for the treatment of LGMD2E/R4. Data are expected in the first half of 2025" @Sarepta on X 2024-12-18 13:37:50 UTC 6156 followers, 3310 engagements
"Today we shared updates from our clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5 2D/R3 and 2E/R4. Read more here:" @Sarepta on X 2025-04-15 12:34:34 UTC 6153 followers, 3401 engagements
"On this #RareDiseaseDay were excited to announce the launch of Route XX The Duchenne Scholarship Program. Were awarding up to XX scholarships to individuals living with Duchenne and up to X scholarships to siblings. Learn more:" @Sarepta on X 2025-02-28 14:07:44 UTC 6156 followers, 1169 engagements
"Excited to be a partner of the 2025 @MDAorg Clinical & Scientific Conference. Well be there celebrating XX years of #MDA impact & sharing updates on how Sarepta is advancing science for Duchenne and LGMD patients. #MDAconference" @Sarepta on X 2025-03-14 20:20:40 UTC 6154 followers, 2760 engagements
"Attending #ASGCT2025 Explore our posters and oral presentations. Learn more here:" @Sarepta on X 2025-05-16 16:03:54 UTC 6154 followers, 1550 engagements
"CEO Doug Ingram on Sareptas global licensing and collaboration agreement with Arrowhead Pharmaceuticals and how the agreement will help solidify Sareptas position as a genetic medicine leader" @Sarepta on X 2024-11-26 14:36:04 UTC 6144 followers, 1802 engagements
"Today we released our financial results for Q4 and the full year of 2024 showing a XX% increase in net product revenue over the same quarter of the prior year. Our president and CEO on the results:" @Sarepta on X 2025-02-26 22:56:51 UTC 6142 followers, 1543 engagements
/creator/twitter::Sarepta